ReviewClinical rheumatology2025
Clinicopathological and imaging differences between pediatric and adult patients with anti-hydroxy-3-methyl-glutaryl-coenzyme A reductase necrotizing myopathy.
Review in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We aimed to elucidate the clinicopathological and imaging differences between pediatric and adult patients with anti-hydroxy-3-methyl-glutaryl-coenzyme A reductase (anti-HMGCR) myopathy. A series of 111 patients with anti-HMGCR myopathy were divided into pediatric (33 patients, onset age < 18 years) and adult (78 patients, onset age ≥ 18 years) groups. Clinical, imaging, and pathological characteristics were compared between the groups. Overall median age at onset was 40 years. Median duration of disease was 12 months. The male:female ratio was 41:70. Prevalence of statin exposure was 0% in the pediatric group and 21% in the adult group (P < 0.001). The prevalence of severe weakness was significantly higher in the pediatric group (63.6% vs. 36.4%; P = 0.008). Myalgia was significantly more frequent in adults (49.3% vs. 20.8%; P = 0.03). The median serum creatine kinase (CK) concentration was significantly higher in the pediatric group (7263.0 vs. 3388.5U/L; P = 0.03). Magnetic resonance imaging of the thigh revealed muscle edema in 82.8% of patients and fatty infiltration in 60.9%. Muscle edema scores in the sartorius (P = 0.02) and gracilis (P = 0.03) were significantly higher in the pediatric group. Fatty infiltration score was significantly correlated with disease duration (r = 0.51; P < 0.001). Dystrophic pathology was significantly more frequent in pediatric patients (47% vs. 8%; P = 0.001). Regeneration score was significantly higher in pediatric group (P = 0.025). Sarcolemmal deposition of membrane attack complex (MAC) was significantly greater in pediatric patients (P = 0.010) and correlated significantly with manual muscle testing-8 score (r = - 0.14; P = 0.04) and serum CK concentration (r = 0.36; P = 0.002). Pediatric patients presented with more severe weakness, higher CK concentration, higher muscle edema score in the sartorius and gracilis, more muscle regeneration, more sarcolemmal MAC deposition, and dystrophic pathology. Adult patients exhibited more myalgia and more minimal changes. Sarcolemmal MAC deposition is a biomarker for disease activity.
Indexed as
Identifiers
39562394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.